Gonsalez Cláudio R, Alcalde Rosana, Nishiya Anna, Barreto Claudia C, Silva Fabio E S, de Almeida Alexandre, Mendonça Marcelo, Ferreira Flavio, Fernandes Simone S, Casseb Jorge, Duarte Alberto J S
Laboratory of Medical Investigation in Dermatology and Immunodeficiencies (LIM-56), University of Sao Paulo Medical School, Sao Paulo, Brazil.
Virus Res. 2007 Nov;129(2):87-90. doi: 10.1016/j.virusres.2007.06.021. Epub 2007 Aug 7.
Primary infection with drug-resistant HIV appears to be increasing in the regions where HAART is widely available, which may reduce efficacy of first-line antiretroviral therapy. To determine prevalence of antiretroviral drug-resistant mutations in newly diagnosed subjects in a clinical setting where HAART has been widely used since 1997. One hundred and thirty-six HIV-1-infected adult patients were diagnosed with HIV infection between January 2000 and December 2006 in the HIV out-clinic at the HC/FMUSP, Sao Paulo city. These antiretroviral naïve patients were mainly referred from the blood bank, situated in the same building or elsewhere in the city. The samples were genotyped to provide HIV protease and reverse transcriptase sequence data. Major antiretroviral drug resistance mutations were classified according to Shafer et al. [Shafer, R.W., Rhee, S.Y., Pillay, D., et al., 2007. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21, 215-223]. Thirteen cases had no DNA amplification, and 123 patients were successfully analyzed, with a mean age of 37 years and 89 (72%) were males. Antiretroviral drug resistance mutations were detected in 8/123 patients (6.5%), all eight were heterosexuals and HIV asymptomatic, the mean of the CD4 cells count was 323 cells/mm(3), and the RNA plasma viral load was 4.7 log(10)/mL. We found NRTI (n=2, 1.6%), NNRTI-resistant (n=2, 1.6%) mutations, and one cases with PI mutation (0.8%). Three cases (2.4%) showed mutations for NRTI, NNRTI or PI, simultaneously. Eighty-two percent were HIV-1 B subtype, and HIV-1 F (6.5%), HIV-1 C (5.7%) and recombinant viruses (5.8%) were observed. In an unselected cohort, primary drug resistance was seen in 6.5% of the naïve for drug ART use. These results indicate that HIV drug resistance testing should be a practical approach in monitoring first-line ART. In addition, HIV-1 C seems to be emerging in Sao Paulo city.
在广泛提供高效抗逆转录病毒治疗(HAART)的地区,耐药性艾滋病毒的初次感染似乎在增加,这可能会降低一线抗逆转录病毒治疗的疗效。为了确定在自1997年以来HAART已被广泛使用的临床环境中,新诊断患者中抗逆转录病毒耐药突变的流行情况。2000年1月至2006年12月期间,在圣保罗市HC/FMUSP的艾滋病毒门诊,136名感染艾滋病毒-1的成年患者被诊断出感染艾滋病毒。这些未接受过抗逆转录病毒治疗的患者主要来自位于同一栋楼或该市其他地方的血库。对样本进行基因分型以提供艾滋病毒蛋白酶和逆转录酶序列数据。主要的抗逆转录病毒耐药突变根据Shafer等人的标准进行分类[Shafer, R.W., Rhee, S.Y., Pillay, D., 等人,2007年。用于耐药监测的艾滋病毒-1蛋白酶和逆转录酶突变。《艾滋病》21卷,215 - 223页]。13例样本无DNA扩增,123例患者成功进行了分析,平均年龄37岁,其中89例(72%)为男性。在123例患者中有8例(6.5%)检测到抗逆转录病毒耐药突变,所有8例均为异性恋且艾滋病毒无症状感染者,CD4细胞计数平均值为323个细胞/mm³,血浆RNA病毒载量为4.7 log(10)/mL。我们发现核苷类逆转录酶抑制剂(NRTI)耐药突变(n = 2,1.6%)、非核苷类逆转录酶抑制剂(NNRTI)耐药突变(n = 2,1.6%),以及1例蛋白酶抑制剂(PI)突变(0.8%)。3例(2.4%)同时出现NRTI、NNRTI或PI的突变。82%为艾滋病毒-1 B亚型,还观察到艾滋病毒-1 F(6.5%)、艾滋病毒-1 C(5.7%)和重组病毒(5.8%)。在一个未经过筛选的队列中,6.5%未接受过抗逆转录病毒治疗的患者出现了原发性耐药。这些结果表明,艾滋病毒耐药性检测应成为监测一线抗逆转录病毒治疗的一种实用方法。此外,艾滋病毒-1 C在圣保罗市似乎正在出现。